Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

A simple test could spot who will develop stomach cancer

NCT ID NCT05782465

Diagnosis Sponsor: National University Hospital, Singapore Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study is testing whether a customized molecular test can identify which people with intestinal metaplasia—a condition that can precede stomach cancer—are at very high risk of developing the disease. Researchers will collect blood and stomach tissue samples from 500 adults aged 50 to 75 and follow them over several years to see if the test's predictions hold true. If it works, the test could help doctors focus surveillance on those who need it most and avoid unnecessary procedures for others.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A molecular test using blood and stomach biopsy samples to assess stomach cancer risk
What this could lead to
If successful, this test could help doctors focus stomach cancer surveillance on those at highest risk, while reducing unnecessary procedures for others.
What could go wrong
The test is still being validated, and it may not accurately predict risk in all patients. It is not yet a proven tool for routine use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2019

Expected to finish

Dec 2033

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants who have been referred to the participating study sites for gastroscopy for clinical indications, and were detected to have IM of OLGIM Stage 2 to 4 at baseline.

Ages

50 to 75 years

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. The subject is above 50 years old or turns 50 years old in the year of recruitment 2. The subject is below 76 years old in the year of recruitment 3. The subject is willing and able to provide signed and dated patient informed consent form indicating that they has been informed of all pertinent aspects of the study Exclusion Criteria: 1. The subject who has bleeding disorders, such as haemophilia, in whom biopsies are contraindicated. 2. The subject with a personal history of high-grade dysplasia or GC. 3. The subject with liver cirrhosis. 4. The subject with previous total or partial gastrectomy. 5. The subject with severe co-morbid illness, such as end-stage renal failure (ESRF), congestive cardiac failure (CCF), severe osteoarthritis (OA), and rheumatoid arthritis (RA) requiring long-term non-steroidal anti-inflammatory drug (NSAID) therapy. 6. The subject with other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may interfere with the interpretation of study results and in the judgement of the investigator would make the subject unsuitable for entry into the study. 7. The subject on regular anti-coagulant prophylaxis such as warfarin must be able to undergo a 5-day washout period before each gastroscopy. The subject on aspirin, ticlopidine and clopidogrel must be able to undergo a one-week washout period before each gastroscopy. The subject's physician or study co-investigator will exercise their clinical judgement to ensure subject's safety. 8. The subject is unwilling or unable to provide signed informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Intestinal metaplasia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

gastric intestinal metaplasia gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stomach neoplasm

Contacts and locations

Locations

  • National Taiwan University Hospital

    Taipei, Taiwan

  • National University Hospital

    Singapore, 119074, Singapore

  • Nihon University School of Medicine

    Tokyo, Japan

  • Singapore General Hospital

    Singapore, 169608, Singapore

  • Stanford University

    Stanford, California, 94305, United States

  • Tan Tock Seng Hospital, Singapore

    Singapore, 308433, Singapore

  • The Chinese University of Hong Kong

    Hong Kong, Hong Kong

  • Yonsei University, Republic of Korea

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.